Skip to main content

Table 1 Pathogens associated with infections caused in the study population

From: Pharmacokinetics of tigecycline in critically ill patients with liver failure defined by maximal liver function capacity test (LiMAx)

 

Total (n = 33)

Group A (n = 5)

Group B (n = 21)

Group C (n = 7)

MIC breakpoints (mg/L)

Microbiological isolate, n (%)

 Enterococcus avium

1 (3)

0

1 (4.8)

0

0.12

 Enterococcus faecalis

3 (9.1)

2 (40)

1 (4.8)

0

0.12

 Enterococcus faecium

11 (33.3)

4 (80)

7 (33.3)

0

0.12

 Escherichia coli

4 (12.1)

2 (40)

2 (9.5)

0

0.5

 MRSA

1 (3)

0

0

1 (14.3)

0.25

 Staphylococcus epidermidis

2 (6.1)

0

3 (14.3)

1 (14.3)

0.12

 VRE

9 (27.3)

2 (40)

3 (14.3)

4 (57.1)

0.12

 ESBL

10 (30.3)

3 (60)

4 (19)

3 (42.9)

0.5

  1. MRSA: methicillin-resistant Staphylococcus aureus; VRE: vancomycin-resistant Enterococci; ESBL: extended betalactamase producing Gram-negative bacteria; MIC: minimum inhibitory concentration